



The Nifty ended 0.31% up at 17377.80. It opened on a flat note and remained range bound throughout the session towards finishing off on a subdued note. Ending the session with a Doji candle implies indecision among traders. Breaking out thick resistance placed in the price range 17450-17500 is the challenge. Failing to breakout 17500 may lead to retracement towards 17200 levels.

On the Nifty hourly chart, direction of the leading indicators suggesting the benchmark index may find it difficult to breakout critical resistance placed around 17500 levels. ADX has started flattening is also a concern for the bulls.

Nifty patterns on multiple periods suggest; it finished off the day with a Doji candle. Doji implies indecision. Hence, staying cautious on rise around 17500 is advised.

Nifty Crucial Supports & Resistances-

Supports- 17200, 17150 Resistances- 17450, 17500

Open Positional Calls-

- T+7 Positional Sell-
|Futures Segment| JSW STEEL Sep Fut @ 700-705, TGT- 665, Closing SL- above 725
- T+7 Positional Sell-
|Futures Segment| TATA MOTORS Fut @ 290-292, TGT- 272, Closing SL- above 302
- T+3 Positional Buy
|Cash Segment| HERO MOTO @ 2790-2780, TGT- 2880, SL- closing below 2730
- T+5 Positional Buy
|Cash Segment| IOC @ 112.50-112, TGT- 118, SL- closing below 109
- T+2 Positional Buy
|Cash Segment| SIEMENS @ 2244-2240, TGT- 2270, SL- closing below 2225
- T+1 Positional Buy
|Cash Segment| TVS MOTOR @ 546-545, TGT- 559, SL- closing below 538
- T+1 Positional Buy
|Cash Segment| TECH MAHINDRA @ 1464-1460, TGT- 1490, SL- closing below 1445

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks closed at record for the third consecutive session, aided by gains in I.T., realty & consumer durables stocks.

Nifty index ended 0.31% higher at 17,378. The broader markets represented by the NIFTY 500 Index ended 0.32% higher, ending at 14,806. Among the sectorial indices, NIFTY Realty was the top gainer, gaining by 3.16%, followed by NIFTY IT gaining by 1.50%. NIFTY PSE was the top loser, losing by 0.47%.

Wipro was the top gainer, gaining by 4.79%, followed by HCL Technologies and Infosys gained by 2.16% & 1.75% respectively. IOCL was the top loser, losing by 1.33%, followed by ONGC and Indusind Bank which fell by 1.18% & 1.18% respectively.

The Advance : Decline ratio stood at 1019:1007

Market Turnover (In Crore) 06-09-2021

Name	Last	Previous
NSE Cash	56272.2	63688.65
NSE F&O	3502349.52	3952884.39
BSE Cash	3,965.16	4,802.95
BSE F&O	33.66	2.27

FII Derivatives Flow (In Crore) 03-09-2021*

Instrument	Purchase	Sale	Net
Index Future	3686.93	4429.35	742.42
Index Option	242744.41	244170.21	1425.8
Stock Future	13886.57	14479.33	592.76
Stock Option	17624.57	17768.71	144.14

Institutional Flow (In Crore) 03-09-2021*

Institution	Purchase	Sale	Net
FII	7492.49	6723.91	768.58
DII	6397.78	5729.18	668.6

*Data not updated till 6PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Wipro	4.79	8.54	12338416	5041347
HCL Technologies	2.16	3.16	4331916	4622825
Infosys	1.75	1.91	4876026	7757254
Hindalco Industries	1.72	4.73	12183840	11299880
RIL	1.55	6.84	15525644	8517368

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Kotak Bank	0.97	2.23	1901931	4985839
Britannia Industries	1.09	2.33	312608	491931
Indusind Bank	1.18	1.31	3349749	3472434
ONGC	1.18	1.25	12505630	14926450
IOCL	1.33	3.96	7535291	14746430

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	58296.91	166.96	0.29	2.47	7.40	11.89	51.98
Nifty	17377.80	54.20	0.31	2.64	7.02	10.90	53.33
BSE M Cap	24425.92	43.73	0.18	3.25	5.26	8.50	64.85
BSE S Cap	27466.66	161.35	0.59	2.91	2.46	13.21	88.09
Nifty MC 100	29178.35	118.30	0.41	3.31	4.41	9.89	72.39
BSE Auto	22796.84	120.06	0.53	1.64	0.79	5.13	26.29
BSE Capgoods	25625.53	65.55	0.26	3.18	7.75	10.08	83.19
BSE FMCG	14784.09	22.50	0.15	2.27	8.04	12.94	29.88
BSE Metal	20666.77	49.62	0.24	1.65	2.29	8.54	131.91
BSE Oil&Gas	17436.42	115.59	0.66	3.26	10.62	1.84	34.80
BSE Healthcare	26759.97	5.19	0.02	2.03	1.48	8.11	42.84
BSE Power	2982.82	15.54	0.52	3.32	11.63	3.36	75.82
BSE Realty	3423.12	98.59	2.97	11.29	6.33	21.46	97.66
BSE ConsDur	39435.75	554.07	1.43	7.18	7.81	12.90	68.81
BSE Bank	41707.14	174.91	0.42	0.95	2.40	4.18	59.59
BSE IT	34920.53	510.62	1.48	3.37	10.24	27.17	92.62

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.32	0.00	0.00	3.43	1.96	14.88	84.16
UK	0.71	0.01	0.98	22.84	16.20	10.13	169.96
Brazil	3.83	0.02	0.53	0.83	1.81	2.35	9.36
Japan	0.05	0.01	21.43	131.82	240.00	41.38	24.39
Australia	1.26	0.04	2.86	8.45	5.71	25.43	41.35
India	6.17	0.02	0.26	0.45	1.01	2.36	4.05
Switzerland	0.32	0.01	2.78	8.43	18.39	123.40	31.37
Germany	0.36	0.00	1.11	18.68	21.71	67.61	24.36

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.11	0.09	0.12	0.23	1.43	0.41	0.33
USD Index	92.27	0.23	0.25	0.42	0.57	2.37	0.49
YUAN	6.46	0.00	0.04	0.13	0.39	0.94	5.77
GBP	1.38	0.00	0.25	0.56	0.25	2.44	5.10
EUR	1.19	0.00	0.12	0.58	0.88	2.66	0.41
YEN	109.87	0.16	0.15	0.05	0.35	0.56	3.28

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	3944.00	57.00	1.42	5.98	17.00	61.77	189.57
Baltic Dirty	616.00	1.00	0.16	1.99	1.15	5.30	38.12
SG Dubai HY	1.74	0.06	3.57	27.94	152.17	93.33	265.71

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	35369.09	74.73	0.21	0.24	0.46	1.76	25.72
Nasdaq	15363.52	32.34	0.21	1.55	3.56	11.21	35.80
S&P 500	4535.43	1.52	0.03	0.58	2.23	7.22	32.35
FTSE100	7187.43	49.87	0.70	0.56	0.92	1.69	23.95
CAC40	6738.44	50.60	0.76	0.80	1.12	3.45	35.76
DAX	15882.11	105.79	0.67	0.00	0.80	1.24	23.70
Mexico IPC	51835.09	252.38	0.48	1.13	1.41	2.68	42.21
Brazil Bovespa	116933.2	256.10	0.22	3.10	4.79	10.14	15.50
Russian RTS	1733.78	1.03	0.06	2.87	6.14	5.23	42.06
Japan Nikkei	29659.89	531.78	1.83	6.73	6.61	2.48	27.81
Hang Seng	26163.63	261.64	1.01	2.44	0.06	9.53	5.95
Taiwan Index	17495.30	21.62	0.12	0.57	0.18	2.03	38.43
Shanghai Comp	3621.86	40.13	1.12	2.66	4.73	0.84	7.94
KOSPI	3203.33	2.27	0.07	1.88	2.05	1.13	35.26
Malaysia KLCI	1581.59	7.60	0.48	0.54	6.16	0.20	4.34
Jakarta Comp	6126.94	0.02	0.00	0.29	1.23	1.02	16.93
Philippine SE	6877.10	20.03	0.29	1.33	5.16	1.19	18.88
Thai Exch	1648.37	1.96	0.12	0.89	8.32	2.29	25.64

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	68.91	0.40	0.58	0.46	0.89	1.05	73.22
BRENT Crude	72.23	0.41	0.56	0.04	2.67	2.57	54.04
Natural Gas	4.75	0.04	0.81	10.34	14.35	52.05	65.05

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1824.49	3.08	0.17	0.79	3.50	3.54	5.65
Silver(\$/Ounce)	24.73	0.01	0.06	2.89	1.65	11.02	8.10
Aluminium	2716.75	28.75	1.07	2.99	5.21	13.93	55.72
Copper	9420.50	56.24	0.60	1.13	1.06	3.57	43.29
Zinc	2985.90	16.90	0.57	0.21	0.91	0.76	20.14
Lead	2399.50	19.50	0.81	1.80	1.60	9.60	25.09

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	193.00	1.35	0.69	0.42	8.52	18.81	43.28
Cotton	94.02	0.73	0.78	0.86	4.62	10.56	44.25
Sugar	19.62	0.28	1.41	2.10	9.12	12.24	56.46
Wheat	726.25	9.25	1.29	0.85	1.16	5.48	25.87
Soybean	1292.00	8.75	0.68	2.36	2.10	7.94	36.14

The Man Company eyes Rs 300 crore net revenue in three years; steps up offline retail expansion

The Man Company aims to log over Rs 300 crore in net revenue in three years as it expands its retail presence in the country via hypermarkets and its own exclusive stores. The company, which is backed by Emami is also looking at achieving break-even by September next year. In our first year, we sold 70,000 units. Since then we have grown manifold and are now targeting 50 lakh product sales by March 2022. We are targeting 50 lakh product sales by March 2022. We are targeting a net realised revenue of Rs 110 crore by March next year and Rs 300-plus crore in three years. the company is currently witnessing 20-25 per cent month-on-month growth, and the company is looking at achieving break-even by September 2022. The company has over 150 employees and 85-100 stock-keeping units (SKUs) of products.

Zydus Cadila gets US Food and Drug Administration nod for diabetes medication

Zydus Cadila has received approval from the US health regulator to market Sitagliptin, a medicine indicated to treat diabetes. The company said its subsidiary has received tentative approval from the United States Food and Drug Administration (FDA) for its new drug application for Sitagliptin base 25, 50 and 100 mg tablets. On October 31, 2020, Zydus had filed a new drug application (NDA) with the USFDA seeking approval to market Sitagliptin base 25, 50 and 100 mg tablets. The NDA received tentative approval upon completion of the first review cycle on September 2, 2021. Zydus Cadila discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines.

Lupin, TB Alliance join hands for new therapy for drug-resistant tuberculosis

Drugmaker Lupin on profit drug developer TB Alliance has granted it a non-exclusive licence to manufacture anti-TB drug pretomanid as part of the three-drug BPaL regimen. The Mumbai-based company said it intends to commercialise the medicine in around 140 countries and territories, including many of the highest TB burden nations around the world. As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health. Lupin is the largest supplier of first-line anti-TB drugs in the world, the drugmaker stated.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Panasonic Carbon India Co Ltd	Cash dividend of INR12 effective 07-09-2021
Anjani Portland Cement Ltd	Cash dividend of INR5 effective 07-09-2021
HEC Infra Projects Ltd	Cash dividend of INR5 effective 07-09-2021

Domestic Events

- No events

Global Events

- China Balance of Trade for August 2021.
- Euro Area GDP FOR Q2 FY22.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com